Using a new strategy, UC San Francisco researchers have succeeded in making small molecules that irreversibly target a mutant form of protein, called ras, without binding to the normal form. This feature distinguishes the molecules from all other targeted drug treatments in cancer, according to the researchers. Read more here.
Study mentioned: Ostrem JM, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013 Nov 20. [Epub ahead of print] PMID: 24256730
No comments:
Post a Comment